Literature DB >> 9230693

The SCL/TAL1 gene: roles in normal and malignant haematopoiesis.

L Robb1, C G Begley.   

Abstract

SCL (TAL1/TCL5) is a member of the helix-loop-helix family of transcription factors. Originally identified because of its involvement in a tumour-specific chromosomal translocation, overexpression of the SCL gene is the most common molecular abnormality found in human T cell leukaemia. Transgenic models have now formally demonstrated that overexpression of SCL within the T cell lineage is capable of causing malignant transformation. Gene targeting experiments have revealed that the SCL gene is crucial for the development of primitive haematopoiesis in the mouse and is also required for the generation of all adult haematopoietic lineages. Biochemical studies have indicated some of the proteins which interact with SCL and this has refined the hypotheses concerning the mechanisms by which SCL plays a role in leukaemogenesis and haematopoietic development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230693     DOI: 10.1002/bies.950190711

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  11 in total

1.  Translational control of SCL-isoform expression in hematopoietic lineage choice.

Authors:  Cornelis F Calkhoven; Christine Muller; Richard Martin; Goradz Krosl; Hubertus Pietsch; Trang Hoang; Achim Leutz
Journal:  Genes Dev       Date:  2003-04-15       Impact factor: 11.361

2.  Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia.

Authors:  Teresa Palomero; Duncan T Odom; Jennifer O'Neil; Adolfo A Ferrando; Adam Margolin; Donna S Neuberg; Stuart S Winter; Richard S Larson; Wei Li; X Shirley Liu; Richard A Young; A Thomas Look
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

3.  Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis.

Authors:  Y Li; C Deng; X Hu; B Patel; X Fu; Y Qiu; M Brand; K Zhao; S Huang
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

4.  Hunting for hematopoietic transcriptional networks.

Authors:  Kenneth Kaushansky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-10       Impact factor: 11.205

Review 5.  Novel insights into the development of T-cell acute lymphoblastic leukemia.

Authors:  Frank J T Staal; Jacques J M van Dongen; Anton W Langerak
Journal:  Curr Hematol Malig Rep       Date:  2007-07       Impact factor: 3.952

6.  Inhibition of all-trans retinoic acid-induced granulocytic differentiation of WEHI-3B D+ cells by forced expression of SCL (TAL1) and GATA-1.

Authors:  Kimiko Ishiguro; Anna M Rice; Kevin P Rice; Alan C Sartorelli
Journal:  Leuk Res       Date:  2009-02-20       Impact factor: 3.156

7.  Predisposition to arrhythmia and autonomic dysfunction in Nhlh1-deficient mice.

Authors:  Tiziana Cogliati; Deborah J Good; Mark Haigney; Petra Delgado-Romero; Michael A Eckhaus; Walter J Koch; Ilan R Kirsch
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

8.  Characterization of hematopoietic progenitor cells that express the transcription factor SCL, using a lacZ "knock-in" strategy.

Authors:  A G Elefanty; C G Begley; D Metcalf; L Barnett; F Köntgen; L Robb
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

9.  Identification and characterization of cell type-specific and ubiquitous chromatin regulatory structures in the human genome.

Authors:  Hualin Xi; Hennady P Shulha; Jane M Lin; Teresa R Vales; Yutao Fu; David M Bodine; Ronald D G McKay; Josh G Chenoweth; Paul J Tesar; Terrence S Furey; Bing Ren; Zhiping Weng; Gregory E Crawford
Journal:  PLoS Genet       Date:  2007-07-02       Impact factor: 5.917

10.  Neuroblastoma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression.

Authors:  Anna Lagergren; Christina Manetopoulos; Håkan Axelson; Mikael Sigvardsson
Journal:  BMC Cancer       Date:  2004-11-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.